Abstract #10551

Pediatric Preclinical Testing Consortium (PPTC) Evaluation of the EZH2 Inhibitor Tazemetostat in Orthotopic PDX Models of Pediatric Brain Tumors

Lin Qi1, Holly Lindsay1, Mari Kogiso1, Stephen Erickson2, John Guo2, Beverly Teicher3, Malcolm A. Smith3, Xiao-Nan Li1
1Baylor College of Medicine, Houston, TX; 2RTI International, Research Triangle Park, NC; 3National Cancer Institute, Bethesda, MD

1. Introduction
Brain Tumor Cells: Animal:
Cell suspension: 1x10^5 cells (2 µL for IC and ICb)

2. Study Methods (continued)

- Experiment Design

3. Results (continued)

   1. Three pediatric GBM PDX models over-express EZH2 mRNA
   
   2. Study Methods: DIPG PDOX models
   
   - Endpoint: Inhibition of EZH2 with tazemetostat given as a single agent or in combination with cisplatin, radiation, or both was not effective at prolonging the survival of group 3 or 4 medulloblastoma PDX models

4. Discussion and Conclusions

   - Inhibition of EZH2 with tazemetostat given as a single agent prolonged the survival of a pediatric GBM PDOX model compared to control, but temozolomide addition to radiation therapy did not prolong survival beyond that observed with radiation alone.

5. References


More information:
Corresponding author: Xiao-Nan Li, MD, PhD, Email: xli25@nih.gov
Supported by: CA016522 and CA196090

Telemetered to PPTC by PPTC Foundation

www.nccifpc.org